2014 SSAT State-of-the-Art Conference

Advances in Diagnosis and Management of Gastroesophageal Reflux Disease

Kyle A. Perry, Thai H. Pham, Stuart J. Spechler, John Hunter, W. Scott Melvin, Vic Velanovich

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Gastroesophageal reflux disease affects at least 10 % of people in Western societies and produces troublesome symptoms and impairs patients’ quality of life. The effective management of GERD is imperative as the diagnosis places a significant cost burden on the United States healthcare system with annual direct cost estimates exceeding 9 billion dollars annually. While effective for many patients, 30–40 % of patients receiving medical therapy with proton pump inhibitors experience troublesome breakthrough symptoms, and recent evidence suggests that this therapy subjects patients to increased risk of complications. Given the high cost of PPI therapy, patients are showing a decrease in willingness to continue with a therapy that provides incomplete relief; however, due to inconsistent outcomes and concern for procedure-related side effects following surgery, only 1 % of the GERD population undergoes anti-reflux surgery annually. The discrepancy between the number of patients who experience suboptimal medical treatment and the number considered for anti-reflux surgery indicates a large therapeutic gap in the management of GERD. The objective of the SSAT State-of-the-Art Conference was to examine technologic advances in the diagnosis and treatment of GERD and to evaluate the ways in which we assess the outcomes of these therapies to provide optimal patient care.

Original languageEnglish (US)
Pages (from-to)458-466
Number of pages9
JournalJournal of Gastrointestinal Surgery
Volume19
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Gastroesophageal Reflux
Therapeutics
Costs and Cost Analysis
Proton Pump Inhibitors
Patient Care
Quality of Life
Delivery of Health Care
Population

Keywords

  • Endoscopic reflux therapy
  • Fundoplication
  • Gastroesophageal reflux
  • GERD

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

2014 SSAT State-of-the-Art Conference : Advances in Diagnosis and Management of Gastroesophageal Reflux Disease. / Perry, Kyle A.; Pham, Thai H.; Spechler, Stuart J.; Hunter, John; Melvin, W. Scott; Velanovich, Vic.

In: Journal of Gastrointestinal Surgery, Vol. 19, No. 3, 2015, p. 458-466.

Research output: Contribution to journalArticle

Perry, Kyle A. ; Pham, Thai H. ; Spechler, Stuart J. ; Hunter, John ; Melvin, W. Scott ; Velanovich, Vic. / 2014 SSAT State-of-the-Art Conference : Advances in Diagnosis and Management of Gastroesophageal Reflux Disease. In: Journal of Gastrointestinal Surgery. 2015 ; Vol. 19, No. 3. pp. 458-466.
@article{9c21a05360974a3180ea77c7945b50e1,
title = "2014 SSAT State-of-the-Art Conference: Advances in Diagnosis and Management of Gastroesophageal Reflux Disease",
abstract = "Gastroesophageal reflux disease affects at least 10 {\%} of people in Western societies and produces troublesome symptoms and impairs patients’ quality of life. The effective management of GERD is imperative as the diagnosis places a significant cost burden on the United States healthcare system with annual direct cost estimates exceeding 9 billion dollars annually. While effective for many patients, 30–40 {\%} of patients receiving medical therapy with proton pump inhibitors experience troublesome breakthrough symptoms, and recent evidence suggests that this therapy subjects patients to increased risk of complications. Given the high cost of PPI therapy, patients are showing a decrease in willingness to continue with a therapy that provides incomplete relief; however, due to inconsistent outcomes and concern for procedure-related side effects following surgery, only 1 {\%} of the GERD population undergoes anti-reflux surgery annually. The discrepancy between the number of patients who experience suboptimal medical treatment and the number considered for anti-reflux surgery indicates a large therapeutic gap in the management of GERD. The objective of the SSAT State-of-the-Art Conference was to examine technologic advances in the diagnosis and treatment of GERD and to evaluate the ways in which we assess the outcomes of these therapies to provide optimal patient care.",
keywords = "Endoscopic reflux therapy, Fundoplication, Gastroesophageal reflux, GERD",
author = "Perry, {Kyle A.} and Pham, {Thai H.} and Spechler, {Stuart J.} and John Hunter and Melvin, {W. Scott} and Vic Velanovich",
year = "2015",
doi = "10.1007/s11605-014-2724-9",
language = "English (US)",
volume = "19",
pages = "458--466",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - 2014 SSAT State-of-the-Art Conference

T2 - Advances in Diagnosis and Management of Gastroesophageal Reflux Disease

AU - Perry, Kyle A.

AU - Pham, Thai H.

AU - Spechler, Stuart J.

AU - Hunter, John

AU - Melvin, W. Scott

AU - Velanovich, Vic

PY - 2015

Y1 - 2015

N2 - Gastroesophageal reflux disease affects at least 10 % of people in Western societies and produces troublesome symptoms and impairs patients’ quality of life. The effective management of GERD is imperative as the diagnosis places a significant cost burden on the United States healthcare system with annual direct cost estimates exceeding 9 billion dollars annually. While effective for many patients, 30–40 % of patients receiving medical therapy with proton pump inhibitors experience troublesome breakthrough symptoms, and recent evidence suggests that this therapy subjects patients to increased risk of complications. Given the high cost of PPI therapy, patients are showing a decrease in willingness to continue with a therapy that provides incomplete relief; however, due to inconsistent outcomes and concern for procedure-related side effects following surgery, only 1 % of the GERD population undergoes anti-reflux surgery annually. The discrepancy between the number of patients who experience suboptimal medical treatment and the number considered for anti-reflux surgery indicates a large therapeutic gap in the management of GERD. The objective of the SSAT State-of-the-Art Conference was to examine technologic advances in the diagnosis and treatment of GERD and to evaluate the ways in which we assess the outcomes of these therapies to provide optimal patient care.

AB - Gastroesophageal reflux disease affects at least 10 % of people in Western societies and produces troublesome symptoms and impairs patients’ quality of life. The effective management of GERD is imperative as the diagnosis places a significant cost burden on the United States healthcare system with annual direct cost estimates exceeding 9 billion dollars annually. While effective for many patients, 30–40 % of patients receiving medical therapy with proton pump inhibitors experience troublesome breakthrough symptoms, and recent evidence suggests that this therapy subjects patients to increased risk of complications. Given the high cost of PPI therapy, patients are showing a decrease in willingness to continue with a therapy that provides incomplete relief; however, due to inconsistent outcomes and concern for procedure-related side effects following surgery, only 1 % of the GERD population undergoes anti-reflux surgery annually. The discrepancy between the number of patients who experience suboptimal medical treatment and the number considered for anti-reflux surgery indicates a large therapeutic gap in the management of GERD. The objective of the SSAT State-of-the-Art Conference was to examine technologic advances in the diagnosis and treatment of GERD and to evaluate the ways in which we assess the outcomes of these therapies to provide optimal patient care.

KW - Endoscopic reflux therapy

KW - Fundoplication

KW - Gastroesophageal reflux

KW - GERD

UR - http://www.scopus.com/inward/record.url?scp=84925541618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925541618&partnerID=8YFLogxK

U2 - 10.1007/s11605-014-2724-9

DO - 10.1007/s11605-014-2724-9

M3 - Article

VL - 19

SP - 458

EP - 466

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 3

ER -